http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 01 Sep 2026 08:03:28 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/MIRA+Pharmaceuticals+reports+positive+toxicology+data+for+MIRA-55+pain+drug/27009231.html <p>MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced positive results from 7-day dose-range finding toxicology and toxicokinetic studies of its investigational drug candidate MIRA-55, an oral non-opioid compound being developed for inflammatory pain.</p><p>The studies, conducted in rats and dogs, characterized tolerability, toxicity, and systemic exposure across both species. Rats were identified as the more sensitive species, while dogs demonstrated greater tolerance across the dose levels studied. Toxicokinetic analyses confirmed systemic exposure in both species and characterized how exposure changed with dose and repeated administration.</p><p>The company said the findings will be used to guide dose selection for the next phase of its IND-enabling http://www.streetinsider.com/Corporate+News/MIRA+Pharmaceuticals+reports+positive+toxicology+data+for+MIRA-55+pain+drug/27009231.html Tue, 01 Sep 2026 08:03:28 -0400 MIRA http://www.streetinsider.com/FDA/MIRA+Pharmaceuticals+reports+positive+toxicology+data+for+MIRA-55+pain+drug/27009231.html <p>MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced positive results from 7-day dose-range finding toxicology and toxicokinetic studies of its investigational drug candidate MIRA-55, an oral non-opioid compound being developed for inflammatory pain.</p><p>The studies, conducted in rats and dogs, characterized tolerability, toxicity, and systemic exposure across both species. Rats were identified as the more sensitive species, while dogs demonstrated greater tolerance across the dose levels studied. Toxicokinetic analyses confirmed systemic exposure in both species and characterized how exposure changed with dose and repeated administration.</p><p>The company said the findings will be used to guide dose selection for the next phase of its IND-enabling http://www.streetinsider.com/FDA/MIRA+Pharmaceuticals+reports+positive+toxicology+data+for+MIRA-55+pain+drug/27009231.html Tue, 01 Sep 2026 08:03:28 -0400 MIRA http://www.streetinsider.com/Press+Releases/MIRA+Pharmaceuticals+Advances+Non-Opioid+Oral+MIRA-55+for+Inflammatory+Pain+Toward+IND/27008975.html <p><strong>Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND Submission</strong></p><p>MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- <strong>MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company")</strong>, a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive results from completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs. MIRA-55 is the Company's investigational oral, non-opioid drug candidate being developed for inflammatory pain.</p> <p><strong>Cross-Species Study Findings</strong></p> <p>The completed studies characterized tolerability, toxicity, and systemic exposure across http://www.streetinsider.com/Press+Releases/MIRA+Pharmaceuticals+Advances+Non-Opioid+Oral+MIRA-55+for+Inflammatory+Pain+Toward+IND/27008975.html Tue, 01 Sep 2026 08:00:00 -0400 MIRA http://www.streetinsider.com/Globe+Newswire/MIRA+Pharmaceuticals+Advances+Non-Opioid+Oral+MIRA-55+for+Inflammatory+Pain+Toward+IND/27008975.html <p><strong>Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND Submission</strong></p><p>MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- <strong>MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company")</strong>, a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive results from completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs. MIRA-55 is the Company's investigational oral, non-opioid drug candidate being developed for inflammatory pain.</p> <p><strong>Cross-Species Study Findings</strong></p> <p>The completed studies characterized tolerability, toxicity, and systemic exposure across http://www.streetinsider.com/Globe+Newswire/MIRA+Pharmaceuticals+Advances+Non-Opioid+Oral+MIRA-55+for+Inflammatory+Pain+Toward+IND/27008975.html Tue, 01 Sep 2026 08:00:00 -0400 MIRA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Jun+30/26913194.html si-local-file:///var/storage/secattach/20260812/26913194.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Jun+30/26913194.html Wed, 12 Aug 2026 16:18:00 -0400 MIRA O.58337359 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Jun+30/26913194.html si-local-file:///var/storage/secattach/20260812/26913194.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Jun+30/26913194.html Wed, 12 Aug 2026 16:18:00 -0400 MIRA O.58337359 http://www.streetinsider.com/Press+Releases/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1/26879165.html <p align="left"><strong>Obesity Treatment Candidate Designed to Preserve Lean Body Mass</strong></p> <p align="left"><strong>Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND</strong></p> <p align="left">MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (&quot;MIRA&quot; or the &quot;Company&quot;), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. The study demonstrates dose-dependent systemic exposure and rapid absorption that de-risk dose selection and support advancement toward GLP toxicology studies and IND-enabling development.</p> <p align="left">The study evaluated SKNY-1 following repeated daily oral http://www.streetinsider.com/Press+Releases/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1/26879165.html Thu, 06 Aug 2026 08:00:00 -0400 MIRA O.58337359 http://www.streetinsider.com/Press+Releases/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1/26879165.html <p align="left"><strong>Obesity Treatment Candidate Designed to Preserve Lean Body Mass</strong></p> <p align="left"><strong>Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND</strong></p> <p align="left">MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (&quot;MIRA&quot; or the &quot;Company&quot;), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. The study demonstrates dose-dependent systemic exposure and rapid absorption that de-risk dose selection and support advancement toward GLP toxicology studies and IND-enabling development.</p> <p align="left">The study evaluated SKNY-1 following repeated daily oral http://www.streetinsider.com/Press+Releases/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1/26879165.html Thu, 06 Aug 2026 08:00:00 -0400 MIRA O.58337359 http://www.streetinsider.com/Globe+Newswire/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1/26879165.html <p align="left"><strong>Obesity Treatment Candidate Designed to Preserve Lean Body Mass</strong></p> <p align="left"><strong>Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND</strong></p> <p align="left">MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (&quot;MIRA&quot; or the &quot;Company&quot;), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. The study demonstrates dose-dependent systemic exposure and rapid absorption that de-risk dose selection and support advancement toward GLP toxicology studies and IND-enabling development.</p> <p align="left">The study evaluated SKNY-1 following repeated daily oral http://www.streetinsider.com/Globe+Newswire/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1/26879165.html Thu, 06 Aug 2026 08:00:00 -0400 MIRA O.58337359 http://www.streetinsider.com/Globe+Newswire/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1/26879165.html <p align="left"><strong>Obesity Treatment Candidate Designed to Preserve Lean Body Mass</strong></p> <p align="left"><strong>Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND</strong></p> <p align="left">MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (&quot;MIRA&quot; or the &quot;Company&quot;), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. The study demonstrates dose-dependent systemic exposure and rapid absorption that de-risk dose selection and support advancement toward GLP toxicology studies and IND-enabling development.</p> <p align="left">The study evaluated SKNY-1 following repeated daily oral http://www.streetinsider.com/Globe+Newswire/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1/26879165.html Thu, 06 Aug 2026 08:00:00 -0400 MIRA O.58337359 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Aug+06/26879212.html si-local-file:///var/storage/secattach/20260806/26879212.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Aug+06/26879212.html Thu, 06 Aug 2026 08:00:00 -0400 MIRA O.58337359 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Aug+06/26879212.html si-local-file:///var/storage/secattach/20260806/26879212.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Aug+06/26879212.html Thu, 06 Aug 2026 08:00:00 -0400 MIRA O.58337359 http://www.streetinsider.com/Press+Releases/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1+/26879081.html <p align="left"><strong>Obesity Treatment Candidate Designed to Preserve Lean Body Mass</strong></p> <p align="left"><strong>Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND</strong></p> <p align="left">MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. The study demonstrates dose-dependent systemic exposure and rapid absorption that de-risk dose selection and support advancement toward GLP toxicology studies and IND-enabling development.</p> <p align="left">The study evaluated SKNY-1 following repeated daily oral http://www.streetinsider.com/Press+Releases/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1+/26879081.html Thu, 06 Aug 2026 08:00:00 -0400 MIRA MIRA http://www.streetinsider.com/Press+Releases/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1+/26879081.html <p align="left"><strong>Obesity Treatment Candidate Designed to Preserve Lean Body Mass</strong></p> <p align="left"><strong>Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND</strong></p> <p align="left">MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. The study demonstrates dose-dependent systemic exposure and rapid absorption that de-risk dose selection and support advancement toward GLP toxicology studies and IND-enabling development.</p> <p align="left">The study evaluated SKNY-1 following repeated daily oral http://www.streetinsider.com/Press+Releases/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1+/26879081.html Thu, 06 Aug 2026 08:00:00 -0400 MIRA MIRA http://www.streetinsider.com/Globe+Newswire/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1+/26879081.html <p align="left"><strong>Obesity Treatment Candidate Designed to Preserve Lean Body Mass</strong></p> <p align="left"><strong>Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND</strong></p> <p align="left">MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. The study demonstrates dose-dependent systemic exposure and rapid absorption that de-risk dose selection and support advancement toward GLP toxicology studies and IND-enabling development.</p> <p align="left">The study evaluated SKNY-1 following repeated daily oral http://www.streetinsider.com/Globe+Newswire/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1+/26879081.html Thu, 06 Aug 2026 08:00:00 -0400 MIRA MIRA http://www.streetinsider.com/Globe+Newswire/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1+/26879081.html <p align="left"><strong>Obesity Treatment Candidate Designed to Preserve Lean Body Mass</strong></p> <p align="left"><strong>Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND</strong></p> <p align="left">MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. The study demonstrates dose-dependent systemic exposure and rapid absorption that de-risk dose selection and support advancement toward GLP toxicology studies and IND-enabling development.</p> <p align="left">The study evaluated SKNY-1 following repeated daily oral http://www.streetinsider.com/Globe+Newswire/MIRA+Reports+Positive+7-Day+Dog+Study+Results+for+SKNY-1+/26879081.html Thu, 06 Aug 2026 08:00:00 -0400 MIRA MIRA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Jul+27/26851543.html si-local-file:///var/storage/secattach/20260731/26851543.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Jul+27/26851543.html Fri, 31 Jul 2026 17:00:00 -0400 MIRA O.58337359 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Jul+27/26851543.html si-local-file:///var/storage/secattach/20260731/26851543.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Jul+27/26851543.html Fri, 31 Jul 2026 17:00:00 -0400 MIRA O.58337359 http://www.streetinsider.com/Corporate+News/MIRA+Pharmaceuticals+completes+toxicology+studies+for+two+drug+candidates/26839267.html <p>MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced it has completed the in-life dosing and scheduled necropsy phases of exploratory, non-GLP, 7-day repeated-dose toxicology and toxicokinetic studies for its two preclinical drug candidates, MIRA-55 and SKNY-1.</p><p>The studies evaluated both candidates in Sprague Dawley rats and Beagle dogs. According to the company, the studies are designed to provide data on tolerability, systemic exposure, and dose selection to inform the design of future GLP-compliant IND-enabling toxicology studies. Sample analysis, toxicokinetic evaluation, and histopathology remain ongoing.</p><p>MIRA-55 is an investigational oral small-molecule candidate targeting chronic inflammatory pain through CB2 receptor pathways. SKNY-1 is an investigational oral http://www.streetinsider.com/Corporate+News/MIRA+Pharmaceuticals+completes+toxicology+studies+for+two+drug+candidates/26839267.html Thu, 30 Jul 2026 08:02:02 -0400 MIRA http://www.streetinsider.com/Press+Releases/MIRA+Pharmaceuticals+Progresses+MIRA-55+and+SKNY-1+Toward+IND-Enabling+Studies/26839104.html <p><strong>Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate Development</strong></p><p>MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- <strong>MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"),</strong> a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced continued advancement of its two lead preclinical programs, MIRA-55, an investigational oral non-opioid drug candidate for chronic inflammatory pain, and SKNY-1, an investigational oral drug candidate for obesity and addiction-related disorders.</p> <p>Over the past several weeks, the Company has advanced both programs through multiple coordinated development activities, including formulation optimization, chemistry, manufacturing and controls (CMC) activities, http://www.streetinsider.com/Press+Releases/MIRA+Pharmaceuticals+Progresses+MIRA-55+and+SKNY-1+Toward+IND-Enabling+Studies/26839104.html Thu, 30 Jul 2026 08:00:00 -0400 MIRA MIRA http://www.streetinsider.com/Press+Releases/MIRA+Pharmaceuticals+Progresses+MIRA-55+and+SKNY-1+Toward+IND-Enabling+Studies/26839104.html <p><strong>Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate Development</strong></p><p>MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- <strong>MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"),</strong> a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced continued advancement of its two lead preclinical programs, MIRA-55, an investigational oral non-opioid drug candidate for chronic inflammatory pain, and SKNY-1, an investigational oral drug candidate for obesity and addiction-related disorders.</p> <p>Over the past several weeks, the Company has advanced both programs through multiple coordinated development activities, including formulation optimization, chemistry, manufacturing and controls (CMC) activities, http://www.streetinsider.com/Press+Releases/MIRA+Pharmaceuticals+Progresses+MIRA-55+and+SKNY-1+Toward+IND-Enabling+Studies/26839104.html Thu, 30 Jul 2026 08:00:00 -0400 MIRA MIRA http://www.streetinsider.com/Globe+Newswire/MIRA+Pharmaceuticals+Progresses+MIRA-55+and+SKNY-1+Toward+IND-Enabling+Studies/26839104.html <p><strong>Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate Development</strong></p><p>MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- <strong>MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"),</strong> a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced continued advancement of its two lead preclinical programs, MIRA-55, an investigational oral non-opioid drug candidate for chronic inflammatory pain, and SKNY-1, an investigational oral drug candidate for obesity and addiction-related disorders.</p> <p>Over the past several weeks, the Company has advanced both programs through multiple coordinated development activities, including formulation optimization, chemistry, manufacturing and controls (CMC) activities, http://www.streetinsider.com/Globe+Newswire/MIRA+Pharmaceuticals+Progresses+MIRA-55+and+SKNY-1+Toward+IND-Enabling+Studies/26839104.html Thu, 30 Jul 2026 08:00:00 -0400 MIRA MIRA http://www.streetinsider.com/Globe+Newswire/MIRA+Pharmaceuticals+Progresses+MIRA-55+and+SKNY-1+Toward+IND-Enabling+Studies/26839104.html <p><strong>Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate Development</strong></p><p>MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- <strong>MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"),</strong> a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced continued advancement of its two lead preclinical programs, MIRA-55, an investigational oral non-opioid drug candidate for chronic inflammatory pain, and SKNY-1, an investigational oral drug candidate for obesity and addiction-related disorders.</p> <p>Over the past several weeks, the Company has advanced both programs through multiple coordinated development activities, including formulation optimization, chemistry, manufacturing and controls (CMC) activities, http://www.streetinsider.com/Globe+Newswire/MIRA+Pharmaceuticals+Progresses+MIRA-55+and+SKNY-1+Toward+IND-Enabling+Studies/26839104.html Thu, 30 Jul 2026 08:00:00 -0400 MIRA MIRA http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Jul+28/26828180.html si-local-file:///var/storage/secattach/20260728/26828180.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Jul+28/26828180.html Tue, 28 Jul 2026 17:00:00 -0400 MIRA O.58337359 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Jul+28/26828180.html si-local-file:///var/storage/secattach/20260728/26828180.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++MIRA+PHARMACEUTICALS%2C+++++For%3A+Jul+28/26828180.html Tue, 28 Jul 2026 17:00:00 -0400 MIRA O.58337359